Highlights from AIDS 2016
Source: 21st International AIDS Conference (AIDS 2016)

Module

In this Expert Analysis, Andrew Carr, MBBS, MD, FRACP, FRCPA; Daniel R. Kuritzkes, MD; and Ian M. Sanne, MBBCH, FCP(SA), provide a comprehensive review of key data on the prevention and management of HIV infection from the 2016 International AIDS Conference.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Critically appraise data from studies of antiretroviral agents when using these therapies to prevent HIV infection
  • Devise management strategies based on the results of recent clinical studies of antiretroviral agents in treatment-naive and treatment-experienced patients
  • Apply best practices for the prevention and management of adverse events associated with HIV, antiretroviral therapy, and comorbidities
  • Provide patient care that appropriately reflects the latest findings regarding the epidemiology and clinical management of coinfections and opportunistic infections

Topics Covered Include:

  • HIV Treatment Studies
  • Dual Therapy Studies
  • Prevention and Vaccine Studies
  • HIV/HCV-Coinfection Studies
  • Comorbidities and Opportunistic Infections
  • HIV Testing and Monitoring Strategies and Tools
 

Faculty

  • Andrew Carr
    MBBS, MD, FRACP, FRCPA
    Daniel R. Kuritzkes
    MD
    Ian M. Sanne
    MBBCH, FCP(SA)

Credit Information

  • Release Date:
    September 23, 2016
  • Expiration Date:
    September 22, 2017
  • Physicians:
    maximum of 1.0 AMA PRA Category 1 Credit

Information on this Educational Activity

Disclosure of Conflicts of Interest

The Annenberg Center assesses conflict of interest with its instructors, planners, managers, and other individuals who are in a position to control the content of CME activities. All relevant conflicts of interest that are identified are thoroughly vetted by the Annenberg Center for fair balance, scientific objectivity of studies utilized in this activity, and patient care recommendations. The Annenberg Center is committed to providing its learners with high-quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Faculty

Andrew Carr, MBBS, MD, FRACP, FRCPA


Professor of Medicine
University of New South Wales
Director, HIV, Immunology,
and Infectious Disease Unit
St Vincent's Hospital
Sydney, Australia

Andrew Carr, MBBS, MD, FRACP, FRCPA, has disclosed that he has received consulting fees from Gilead Sciences, Mayne Pharma, MSD, and ViiV Healthcare; funds for research support from Bristol-Myers Squibb, Gilead Sciences, MSD, and ViiV Healthcare; and fees for non-CME/CE services received directly from a commercial interest or their agents (eg, speaker bureaus) from Gilead Sciences, MSD, and ViiV Healthcare.
 

Daniel R. Kuritzkes, MD


Chief, Division of Infectious Diseases
Brigham and Women's Hospital
Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Daniel R. Kuritzkes, MD, has disclosed that he has received consulting fees from Bionor, CytoDyn, Gilead Sciences, GlaxoSmithKline, InnaVirVax, Janssen, Merck, Oncolys, Teva, United BioPharma, ViiV Healthcare, and ViroStatics; funds for research support from Gilead Sciences; and fees for non-CME/CE services received directly from a commercial interest or their agents (eg, speaker bureaus) from United BioPharma.
 

Ian M. Sanne, MBBCH, FCP(SA)


Associate Professor, Internal Medicine and Infectious Diseases
Clinical HIV Research Unit
Department of Medicine
Faculty of Health Sciences
University of the Witwatersrand
Johannesburg, South Africa

Ian M. Sanne, MBBCH, FCP(SA), has disclosed that he has received consulting fees from GlaxoSmithKline, Merck, and ViiV Healthcare.
 

Staff

Jennifer M. Blanchette, PhD


Managing Editor

Jennifer M. Blanchette, PhD, has no real or apparent conflicts of interest to report.
 

Megan K. Murphy, PhD


Clinical Editor

Megan Murphy, PhD, has no real or apparent conflicts of interest to report.
 

Jenny Schulz, PhD


Editorial Director, Virology & Other Therapeutic Areas

Jenny Schulz, PhD, has no real or apparent conflicts of interest to report.
 

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

The following planners and managers, Trace Hutchison, PharmD, Samantha Mattiucci, PharmD, CHCP, Judi Smelker-Mitchek, RN, BSN and Jan Schultz, RN, MSN, CHCP, hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

Charles E. Willis, MBA, Director of Continuing Education, Amanda Sewell, MBA, Manager of Continuing Education, Debbie Price, Registration Database Administrator, and Alma Perez, Accreditation Specialist from the Annenberg Center for Health Sciences at Eisenhower have no relevant commercial relationships to disclose.

Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The Annenberg Center, Postgraduate Institute for Medicine (PIM), Clinical Care Options, and activity supporters do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the Annenberg Center, PIM, Clinical Care Options, and activity supporters. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

 

Target Audience

This program is intended for physicians, registered nurses, and other healthcare professionals involved in the care of patients with HIV.


Goal

The goal of this activity is to improve participants’ competence in translating the most clinically significant data from the 2016 International AIDS Conference into practical management strategies for patients infected with or at risk of acquiring HIV.


Learning Objectives

Upon completion of this activity, participants should be able to:

  • Critically appraise data from studies of antiretroviral agents when using these therapies to prevent HIV infection
  • Devise management strategies based on the results of recent clinical studies of antiretroviral agents in treatment-naive and treatment-experienced patients
  • Apply best practices for the prevention and management of adverse events associated with HIV, antiretroviral therapy, and comorbidities
  • Provide patient care that appropriately reflects the latest findings regarding the epidemiology and clinical management of coinfections and opportunistic infections
 

Physician Continuing Medical Education

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC. The Annenberg Center for Health Sciences at Eisenhower is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation

The Annenberg Center for Health Sciences at Eisenhower designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

 

Commercial Support


This program is supported by an educational grant from ViiV Healthcare.

 

Program Medium


This program has been made available online.

 

Site Requirements


  • Internet Explorer 7+, Firefox 3+, Safari 3+, or Chrome
  • JavaScript enabled
  • 1024x768+ screen resolution
  • Adobe Flash Player
 

Instructions for Credit

Participation in this self-study activity should be completed in approximately 1 hour. To successfully complete this activity and receive credit, participants must follow these steps during the period from September 23, 2016, through September 22, 2017:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME activities completed can be found on the "CME Manager" page. There are no costs/fees for this activity.

  • The Imperative for Women-Initiated HIV Prevention Technologies

    Quarraisha Abdool Karim PhD - 7/8/2016    1 comment / Last Comment: 7/11/2016
    Professor Quarraisha Abdool Karim, PhD, introduces her take on one of the key challenges for women at risk of HIV infection and evolving strategies for prevention. At an upcoming symposium in Durban, Catherine Hankins, MD, PhD, FRCPC, CM, and a multidisciplinary panel of experts will continue this discussion by providing their perspectives on 3 global challenges to treatment and prevention of HIV in women.
  • Switch Strategies in Virologically Suppressed Patients: My Take on New Data From Recent Scientific Meetings

    Anton L. Pozniak MD, FRCP - 1/22/2016    15 comments / Last Comment: 11/14/2016
    Several recent studies have highlighted new approaches to ART switching. Some may expand our options for optimizing long-term virologic suppression in our patients; each should be scrutinized carefully before incorporating into practice.
  • Why ART Trials Specific to Women Are Important

    Kathleen E. Squires MD - 9/28/2016    2 comments / Last Comment: 10/19/2016
    Although almost one half of new HIV infections worldwide occur in women, to date, clinical trials for FDA-approved ART regimens have largely been conducted in men. Here is my take on why women-specific ART trials are important.
  • ART in Older Patients: How I Manage Drug–Drug Interactions With Concomitant Medications

    Anton L. Pozniak MD, FRCP - 10/20/2015    16 comments / Last Comment: 5/10/2016
    As our patients age, they experience metabolic changes and more frequently develop conditions such as bone mineral density loss, cardiovascular disease, diabetes, and malignancies, all of which will affect the choice of first-line ART.
  • My Approach to First-line ART for Patients With High Cardiovascular Disease Risk

    William G. Powderly MD - 10/6/2015    4 comments / Last Comment: 11/8/2015
    When treating HIV in patients with risk factors for CVD, selecting the optimal ART regimen is only part of the equation.